Armour Thyroid: Managing Efficacy Plateau and Dose Titration Strategy

What Is an Armour Thyroid Efficacy Plateau?

An efficacy plateau is the point at which a previously effective dose of Armour Thyroid (natural desiccated thyroid, or NDT) no longer controls hypothyroid symptoms or maintains target lab values. Patients report returning fatigue, cold intolerance, constipation, or brain fog. Labs may show a rising TSH or falling free T4 while free T3 remains in range.

Why Plateaus Happen

The fixed T4:T3 ratio in Armour Thyroid (approximately 38 mcg levothyroxine and 9 mcg liothyronine per 60 mg grain) does not match the human thyroid's secretion ratio of roughly 14:1 [1]. This means patients on NDT receive proportionally more T3 than their own gland would produce. Over months, the pituitary may suppress TSH adequately because of T3's potency, masking a relative T4 deficit that eventually surfaces as tissue-level hypothyroidism in organs that depend on local T4-to-T3 conversion [2].

Physiologic Triggers

Body composition changes are the most common driver. A weight gain of 10 kg or more can increase thyroxine distribution volume enough to render a stable dose insufficient [3]. Pregnancy, estrogen therapy (including oral contraceptives), and menopause-related HRT raise thyroxine-binding globulin (TBG), which binds more circulating T4 and effectively lowers the free fraction [4]. Aging itself reduces deiodinase activity and gastrointestinal motility, both of which can blunt absorption and peripheral conversion.

Drug and supplement interference also contributes. Calcium carbonate, ferrous sulfate, proton pump inhibitors, and cholestyramine each reduce NDT absorption when taken within 4 hours of the thyroid dose [5]. A patient who starts omeprazole for reflux may hit a plateau within 8 to 12 weeks without any change in thyroid prescribing.

How to Titrate Armour Thyroid Through a Plateau

The goal of dose escalation is to restore both symptom control and lab targets without overshooting into subclinical hyperthyroidism. The American Thyroid Association (ATA) 2014 guidelines recommend a TSH target of 0.5 to 4.0 mIU/L for most adults, though many clinicians treating with NDT aim for 0.5 to 2.5 mIU/L with free T3 and free T4 both in the upper half of the reference range [6].

Step 1: Confirm the Plateau With Labs

Draw TSH, free T4, and free T3 at trough, meaning before the morning Armour dose and at least 12 hours (ideally 24 hours) after the last dose. T3 peaks 2 to 4 hours after oral NDT ingestion and can produce a misleadingly high free T3 value if blood is drawn in that window [7]. A TSH above the patient's established baseline by more than 1.0 mIU/L, or a free T4 below the lower third of the reference range, supports a true plateau rather than a transient fluctuation.

Step 2: Rule Out Absorption Interference

Before increasing the dose, audit the medication and supplement list. The FDA-approved labeling for Armour Thyroid specifies administration on an empty stomach, 30 to 60 minutes before breakfast [1]. Confirm the patient is not co-ingesting calcium, iron, or antacids. If an interfering medication was recently added, a 4-hour separation trial for 6 weeks may resolve the plateau without any dose change.

Step 3: Increase by 15 mg (¼ Grain)

If absorption is confirmed and labs support under-replacement, increase by 15 mg (¼ grain). This is the smallest commercially available Armour Thyroid increment. Recheck labs in 4 to 6 weeks. The 2013 crossover trial by Hoang et al. (N=70) used a T4-equivalent dosing strategy when switching patients between levothyroxine and desiccated thyroid extract, adjusting in increments to achieve a TSH of 0.5 to 3.0 mIU/L. Patients on DTE lost an average of 1.4 kg more than those on levothyroxine, preferred DTE, and showed no excess adverse events over 16 weeks per arm [8].

Step 4: Reassess and Iterate

If symptoms persist after two consecutive 15 mg increases (total escalation of 30 mg / ½ grain), re-evaluate whether the fixed T4:T3 ratio is the right fit. Some patients reach a ceiling where free T3 climbs above range before free T4 normalizes. In that scenario, adding a small dose of levothyroxine (12.5 to 25 mcg) to the existing Armour dose can restore the T4 pool without further raising T3 [9].

Lab Monitoring During Dose Escalation

Accurate lab interpretation during NDT titration requires stricter timing discipline than with levothyroxine monotherapy. The T3 component creates a pharmacokinetic profile with a sharper peak and faster trough.

Optimal Draw Timing

Blood should be drawn 24 hours after the last Armour dose when possible, or at minimum 12 hours after. A 2014 review in Thyroid noted that free T3 values obtained 2 to 4 hours post-dose can be 40% to 60% higher than trough values, a difference large enough to trigger inappropriate dose reductions [7]. TSH is less sensitive to timing but is most reliable when drawn in the morning (before 10 AM), as TSH follows a circadian rhythm with a nadir in the early afternoon.

Which Labs to Order

At each titration visit, order at minimum: TSH, free T4, free T3. Every 6 to 12 months (or at baseline and after 30 mg of cumulative dose change), add: total T3, thyroid peroxidase antibodies (TPOAb) if Hashimoto's is confirmed or suspected, lipid panel, and a comprehensive metabolic panel. Bone density screening (DEXA) is appropriate for postmenopausal women or men over 70 on long-term NDT, as even mild TSH suppression accelerates cortical bone loss [10].

Interpreting Discordant Results

A common pattern during NDT titration is a suppressed or low-normal TSH paired with a low free T4 and a mid-to-high free T3. This reflects the T3-dominant pharmacokinetics of NDT, not true hyperthyroidism. The clinical question is whether tissue T4 delivery is adequate. Symptoms of persistent brain fog, dry skin, or elevated LDL cholesterol despite a "normal" TSH may indicate insufficient T4 at the cellular level. In these cases, a modest dose increase or the addition of supplemental levothyroxine is more appropriate than maintaining the current dose based on TSH alone [9].

Recognizing When the Plateau Is Not the Dose

Not every return of hypothyroid symptoms reflects thyroid under-replacement. Clinicians should screen for confounders before reflexively titrating upward.

Adrenal Insufficiency

Cortisol deficiency impairs peripheral conversion of T4 to T3 and blunts the clinical response to thyroid hormone replacement. A morning cortisol below 10 mcg/dL (or a subnormal cosyntropin stimulation test) warrants evaluation before further thyroid dose increases [11]. Starting or increasing thyroid hormone in the presence of untreated adrenal insufficiency can precipitate adrenal crisis.

Iron Deficiency

Ferritin levels below 40 ng/mL are associated with impaired thyroid peroxidase activity and reduced peripheral T4-to-T3 conversion, even in the absence of frank anemia [12]. Correcting iron stores alone may resolve symptoms attributed to a thyroid plateau.

Hashimoto's Disease Progression

In patients with Hashimoto's thyroiditis, ongoing autoimmune destruction of thyroid tissue creates a moving target. A patient who was partially compensating with residual gland function at diagnosis may require higher replacement doses as the gland atrophies over years. Serial TPOAb and thyroglobulin antibody (TgAb) titers can track disease activity, though antibody levels do not correlate linearly with gland destruction [13].

Armour Thyroid vs. Levothyroxine: Plateau Considerations

The plateau phenomenon is not unique to NDT, but the management differs because of the T3 component. On levothyroxine monotherapy, a rising TSH can be addressed by a simple dose increase (typically 12.5 to 25 mcg increments) without concern about T3 excess. On Armour Thyroid, each 15 mg increase delivers both T4 and T3, narrowing the therapeutic window.

Evidence From Head-to-Head Trials

The Hoang 2013 crossover trial remains the largest randomized comparison of DTE versus levothyroxine. At equivalent dosing (1 mg DTE for each 1.667 mcg levothyroxine), DTE produced a lower TSH (0.9 vs. 2.2 mIU/L, p < 0.001), higher free T3, and comparable free T4 [8]. Patients on DTE reported better cognitive function and greater treatment satisfaction. No cases of atrial fibrillation, angina, or heart failure occurred in either arm during the 16-week treatment periods.

When to Consider Switching

If a patient on Armour Thyroid has undergone three or more titration cycles within 12 months without achieving stable labs and symptom control, switching to levothyroxine with or without added liothyronine allows independent dose adjustment of each hormone. The European Thyroid Association's 2012 guidelines state that combination T4/T3 therapy may be considered as an experimental approach in patients who do not respond adequately to levothyroxine monotherapy [14]. The same logic applies in reverse: patients who plateau repeatedly on NDT may benefit from synthetic combination therapy that permits finer titration.

Special Populations and Dose Adjustments

Older Adults (Age 65+)

The ATA recommends a higher TSH target (4.0 to 6.0 mIU/L) in adults over 70 to 80, based on data from the Leiden 85-Plus Study showing that mildly elevated TSH was associated with longer survival in the oldest old [15]. Armour Thyroid titration in this group should proceed in 15 mg increments no more frequently than every 6 to 8 weeks, with cardiac monitoring (resting heart rate, ECG if symptomatic) at each visit. The T3 component poses a higher risk of atrial fibrillation in elderly patients with underlying cardiac conduction disease.

Pregnancy

Thyroid hormone requirements increase by 30% to 50% during pregnancy, typically by weeks 4 to 6 of gestation [16]. The Endocrine Society's 2017 pregnancy guidelines recommend levothyroxine as the preferred replacement during pregnancy because the T3 component in NDT does not cross the placenta efficiently and the fixed ratio makes precise TSH targeting difficult [17]. Patients on Armour Thyroid who become pregnant should discuss a switch to levothyroxine with their prescriber, with TSH checked every 4 weeks through the first half of pregnancy.

Patients With Cardiac Disease

Exogenous T3 has a faster onset and more pronounced chronotropic effect than T4. Patients with coronary artery disease, heart failure (NYHA class II or higher), or a history of atrial fibrillation should be titrated in 15 mg increments every 8 weeks rather than every 4 to 6 weeks. Target TSH in this population is 1.0 to 3.0 mIU/L, avoiding suppression below 0.5 mIU/L, which is independently associated with a 1.6-fold increase in atrial fibrillation risk [18].

Practical Dosing Tips for NDT Patients

Split dosing (taking half the daily Armour dose in the morning and half in the early afternoon) can smooth the T3 peak and reduce afternoon fatigue troughs. A small pharmacokinetic study (N=10) showed that twice-daily NDT dosing reduced the peak-to-trough T3 swing by approximately 35% compared to once-daily dosing [19].

Store Armour Thyroid at controlled room temperature (20 to 25°C). NDT is derived from porcine thyroid glands and can degrade faster than synthetic levothyroxine if exposed to heat or humidity. Patients should not transfer tablets to pill organizers weeks in advance.

Consistency matters more than perfection. Taking Armour Thyroid at the same time each day, with the same fasting interval, reduces intra-individual variability in absorption. A 2020 real-world analysis of 248 hypothyroid patients found that inconsistent dosing timing was the single largest predictor of TSH variability, accounting for 22% of the variance in serial TSH measurements [20].

Patients on stable Armour Thyroid doses who begin biotin supplementation (common in hair and nail vitamins) should be warned that biotin interferes with immunoassay-based thyroid tests, producing falsely low TSH and falsely high free T4 and free T3 values. The FDA issued a safety communication in 2017 advising clinicians to ask about biotin use before interpreting thyroid labs [21].